Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.
Faricimab versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
Skin of Color Savvy—A New Generation of Dermatology Leadership, With Umayr Shaikh, MPH
3
Diabetes Dialogue: Signos and the Science of Weight Loss
4
Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework
5